Viridian Continues Building Case For Veligrotug In TED

16 Dec 2024

Looking to compete with Amgen’s Tepezza, veligrotug has now met efficacy and safety endpoints in active and chronic patients, while offering less burdensome dosing.

Viridian gets strong data in chronic TED patients (Shutterstock)

Viridian unveiled successful across-the-board Phase III data on 16 December for veligrotug in chronic thyroid eye disease (TED), roughly three months after similar broad Phase III success with the candidate in active TED. Now, the company is planning to file a biologic licensing application at the US Food and Drug Administration in the second half of 2025 with hopes for a product launch in 2026.

Key Takeaways

Viridian demonstrates safety and efficacy in a Phase III chronic thyroid eye disease study just months after succeeding with the same drug in active TED.

Veligrotug is an intravenously delivered insulin-like growth factor-1 receptor (IGF-1R) antibody, the same drug class as the current standard of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

20 Jun 2025

• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

19 Jun 2025

• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.